Core Viewpoint - The approval of the Duanjin Detox Capsule by the National Medical Products Administration remains uncertain despite achieving expected results in Phase I clinical trials, leading to a decline in the company's stock price [1][3]. Group 1: Product Development and Clinical Trials - The Duanjin Detox Capsule is developed based on folk remedies for treating opioid addiction, with main ingredients including Kouwen and Yangjinhua [1]. - The company has invested approximately 98.283 million yuan in the development of the Duanjin Detox Capsule since starting clinical trials in 2019 [1]. - Three clinical studies have been completed, involving 114 healthy adult participants, demonstrating good safety and tolerability of the capsule [3]. Group 2: Market Context and Efficacy - The relapse rate for opioid users after detoxification is high, with 77.7% relapsing within three months and over 95% within six months [2]. - Clinical findings indicate that the Duanjin Detox Capsule shows promising efficacy in preventing relapse, with a one-year relapse rate as low as 30% for treated individuals [2]. - The capsule is expected to provide at least 12 weeks of sustained relapse prevention effects after a short-term use of 21 days [2]. Group 3: Financial Impact and Company Performance - The company reported a revenue of 2.635 billion yuan in the first half of 2025, a year-on-year increase of 0.11%, and a net profit of 304 million yuan, up 19.91% [4]. - The company anticipates that the approval and subsequent market launch of the Duanjin Detox Capsule will have a significant positive impact on its future performance [3].